Patient Blood Management
Simon Stanworth, DPhil, MD
Professor of Haematology and Transfusion Medicine
University of Oxford
Oxford, England, United Kingdom
Disclosure(s): No financial relationships to disclose
Jeffrey Carson, MD (he/him/his)
Provost and Distinguished Professor of Medicine
Rutgers Robert Wood Johnson Medical School
Princeton, New Jersey, United States
Disclosure(s): Cerus Corporation: Chair of DSMB for trial. Attended meeting to discuss trial results (Ongoing)
Aryeh Shander, MD, FCCM, FCCP, FASA
Englewood Health
North Palm Beach, Florida, United States
Disclosure(s): CSL-Vifor, Pharmacosmos, iSep, Lindis Corp, Accumen, Octapharma: Consultant/Advisory Board (Ongoing)
Session Desription: The Myocardial and Ischemia Trial (MINT) was published in December 2023. MINT enrolled 3504 patients with acute myocardial infarction and hemoglobin concentration less than 10 g/dL and randomly allocated participants to either a liberal transfusion strategy that required transfusion to maintain hemoglobin concentration greater than or equal 10 g/dL or a restrictive transfusion strategy that permitted transfusion below 8 g/dL and strongly recommended transfusion below 7 g/dL. The investigators concluded “In patients with acute myocardial infarction and anemia, a liberal transfusion strategy did not significantly reduce the risk of recurrent myocardial infarction or death at 30 days. However, potential harms of a restrictive transfusion strategy cannot be excluded.” The clinical implications of this large study continue to be discussed. In addition, this trial data is now being incorporated into meta-analyses together with other trials conducted in the setting of acute myocardial infarction and anemia.
Following the successful format of a debate at the 2023 AABB meeting, two speakers will now debate whether anemic patients with acute myocardial infarction should be managed with a liberal or restrictive transfusion strategy, and provide arguments for and against each approach.